Reactogenicity, Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults

Trial Profile

Reactogenicity, Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Supra-seasonal-universal-influenza-vaccine-inactivated-GlaxoSmithKline (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Acronyms FLU D-SUIV-ADJ-001
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 30 Oct 2017 Planned number of patients changed from 450 to 470.
    • 09 Oct 2017 Planned End Date changed from 29 Mar 2020 to 5 Apr 2020.
    • 09 Oct 2017 Planned primary completion date changed from 29 Mar 2020 to 5 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top